Mergers & Acquisitions ·
Apogee Therapeutics stockholders approved the proposed merger with AbbVie subsidiary Andor LLC at a special meeting on…
APGEApogee Therapeutics, Inc.
Apogee Therapeutics stockholders approved the proposed merger with AbbVie subsidiary Andor LLC at a special meeting on August 11, 2026. The Merger Proposal received 46,508,107 votes in favor against 3,885 opposed and 14,261 abstentions, representing approximately 74.87% of outstanding voting shares present or represented by proxy. This approval satisfies a closing condition for the transaction, which will result in Apogee becoming an indirect wholly-owned subsidiary of AbbVie. Conversely, the advisory vote on merger-related executive compensation was rejected, with 27,123,259 votes against and only 19,323,605 in favor. In connection with the anticipated closing, all eight current directors have indicated their intention to resign effective upon the Merger's completion. Apogee Therapeutics is a biopharmaceutical company focused on developing treatments for inflammatory diseases.